Ultragenyx Pharmaceutical (RARE) Receivables (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Receivables data on file, last reported at $40.0 million in Q1 2026.

• Quarterly Receivables fell 7.41% year-over-year to $40.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.0 million (down 7.41% YoY) and the FY2025 annual result came in at $99.0 million, up 13.79% from the prior year.
• Receivables eased to $40.0 million in Q1 2026 per RARE's latest filing, from $99.0 million in the prior quarter.
• Across five years, Receivables topped out at $125.4 million in Q2 2025 and bottomed at $18.4 million in Q3 2022.
• The 5-year median for Receivables is $74.5 million (2023), against an average of $70.0 million.
• The widest annual swing landed in 2023, when Receivables soared 332.95%; it then sank 56.99% in 2025.
• Tracing RARE's Receivables over 5 years: stood at $46.8 million in 2022, then soared by 59.01% to $74.5 million in 2023, then gained by 16.79% to $87.0 million in 2024, then rose by 13.79% to $99.0 million in 2025, then tumbled by 59.6% to $40.0 million in 2026.
• Per Business Quant, the three latest RARE Receivables figures stand at $40.0 million (Q1 2026), $99.0 million (Q4 2025), and $114.6 million (Q3 2025).

Peer Comparison